Talicia (Omeprazole/Amoxicill/Rifabutin) Patent Expiration, LOE Window & CMS Spending
Talicia (Omeprazole/Amoxicill/Rifabutin) by Talicia Holdings: FDA Orange Book LOE 2042-05-27, 0 AB generics, $7.2M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Talicia Holdings |
| FDA Application & Pathway | N213004 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2042-05-27 |
| Orange Book Patents (*PED Extensions) | 7 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $7.2M |
| 2024 Medicare Part D Spend | $2.6M |
| 2024 Medicaid Spend | $4.6M |
| Reported Wholesale Price Change (CA SB 17) | 6 WAC filings (max 21.4% 2-yr change) |